NCT01155219View on ClinicalTrials.gov

Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

PHASE4CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

December 31, 2009

Conditions

Glaucoma

Interventions

DRUG

Geltim LP 1 mg/g

one drop in the conjunctival sac of each eye in the morning (84 days).

DRUG

Xalatan

one drop in the conjunctival sac of each eye in the morning (84 days).

Trial Locations (1)

63000

Clermont-Ferrand

Sponsors

Lead Sponsor

Laboratoires Thea

All Listed Sponsors

lead

Laboratoires Thea

INDUSTRY